Idorsia
Luca Franceschini has a comprehensive work experience in human resources and leadership roles. Luca is currently working as the Head of Human Resources for the EUCAN Region at Idorsia Pharmaceuticals Ltd since 2021. Prior to this, they served as an HR Business Partner at GSK from April 2021 to October 2021.
Before joining GSK, Luca worked at Celgene, where they held multiple positions including Integration Lead, Sr. Director HR Italy & Central Northern Europe, and HR Director Italy. During their time at Celgene, Luca focused on business continuity, organizational design, and change management. Luca also collaborated closely with executives to address talent-related issues and foster a supportive work culture.
Prior to Celgene, Luca worked at Cementir Holding S.p.A., where they served as the Human Resources & Organization Director and the Global People Performance Development Manager from 2010 to 2015. Luca also had experience as an HR Business Partner Manager at LeasePlan from 2008 to 2010, and as a Recruiting, Training & Development Manager at Johnson & Johnson from 2002 to 2008.
Luca Franceschini's education history includes: a Master in Direzione ed Organizzazione del Personale from Luiss Business School in 2001-2002; a Master in Creative Coaching from Nostopevolution in 2020; a Master in LIFE AND CORPORATE COACHING in 2008-2009; a Corso di analisi grafologica in 2000-2003; and a Laurea in Psicologia del lavoro e delle organizzazioni from Sapienza Università di Roma in 1994-2000.
This person is not in any teams
This person is not in any offices
Idorsia
4 followers
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.